On August 21, the Health Resources and Services Administration (HRSA), part of the U.S. Department of Health and Human Services, published a Proposed Rule that would further delay the effectiveness of a final rule on calculation of drug price ceilings and the imposition of civil monetary penalties for manufacturers that knowingly and intentionally overcharge covered entities under the 340B Drug Pricing Program. Comments on the Proposed Rule are due by September 20.
Implementation of the final rule, originally released in January and previously discussed here, had already been postponed three times this year, most recently until October 1, 2017. Under the Proposed Rule, it would be further delayed until July 1, 2018, while HRSA "continues to examine important substantive issues" covered under the final rule.
For more articles and regular updates on legislative changes, regulatory developments and other news of interest to businesses, professionals and investors in the healthcare industry, please subscribe to Day Pitney's mailing lists.
Click here for more Healthcare Blogs from Day Pitney
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
